



SMART
NANOVIRUS

RIGVIR SE

- The world's first food supplement with a live harmless virus
- For people with an increased risk of developing cancer and with a weakened immune system
- Based on science, medicine and long-term pre-clinical and clinical practice

RIGVIR SE

Rigvir SE description

Rigvir SE is recommended to people with a weakened immune system and with an increased risk of developing cancer.

Rigvir SE contains:


- Adapted non-genetically modified and non-pathogenic oncolytic ECHO-7 virus Rigvir – the same live virus as in the anti-cancer medicine Rigvir
- Vitamin B2 and whey protein isolate

Contains milk; does not contain gluten, wheat, yeast or soy.

Rigvir SE ingredients are included in a special capsule that allows it to cross the stomach and reach the intestine which is the most suitable environment for the ECHO-7 virus.

Rigvir SE active ingredient ECHO-7 virus is internationally patented.

Mode of action



Effect

Rigvir SE has a dual effect: immunomodulatory, which induces the body's immune defences, and oncolytic, which affects cancer cells. The initial immune effect can be detected 2-6 days after Rigvir SE intake by complete blood count test. The immune effect manifests itself mostly as increase of leukocyte, neutrophil and lymphocyte count. Over a longer period of time it is possible to detect a positive effect of the ECHO-7 virus on the CD4+ and CD8+ T cells, B lymphocytes and Natural killer (NK) cells. Direct oncolytic effect towards cancer cells of the ECHO-7 virus lasts for approximately 7 days; indirect effect may last for up to one month.

Quality

The quality of Rigvir SE is checked on several levels:

- During production
- While it is on the market
- During storage in partner warehouses to ensure the required storage and monitoring conditions

Independent third-party laboratories perform regular random Rigvir SE sample selection for sterility and stability testing.

Safety

Rigvir SE has completed the necessary tests, including safety, several toxicology and sterility tests. The ingredients have been separately tested for many years. This particular ECHO-7 virus is specially adapted for various cancer cell recognition. It is non-pathogenic and non-genetically modified; its harmlessness has been proved in long-term clinical practice and pre-clinical trials even with a multiple times greater dose compared to the one in Rigvir SE, ensuring an excellent safety and tolerance profile.

Smart Nanovirus Limited

The producer of Rigvir SE is a UK-based company Smart Nanovirus Limited that has received an exclusive licence from the Rigvir Group for the use of ECHO-7 Rigvir virus and Rigvir trademark in non-medical product development.

WWW.SMARTNANOVIRUS.COM



RIGVIR SE

Target audience

People with a weakened immune system and increased cancer risks:

- Precancerous diseases (mycoplasmosis and toxoplasmosis, chronic obstructive pulmonary disease (COPD), Helicobacter pylori infection, human papillomavirus (HPV), polyps, diabetes etc.)
- Genetic predisposition
- Increased tumour markers
- Age above 65

In cases of an existing clinical diagnosis of cancer, Rigvir SE may be used for metastasis prevention or as a complementary therapy.

According to the World Health Organization, one in five men or women worldwide will develop cancer during their lifetime, and one in eight men and one in eleven women will die from it.

Manufacturing

Manufacturing of Rigvir SE is a biotechnologically complicated, yet environmentally friendly process without harmful waste and emissions. Rigvir SE is manufactured in the European Union in GMP facilities according to the best pharmacy practices.

Storage

Keep refrigerated (at optimum +4°C). Improper storage conditions will cause product degradation. Transport at a temperature up to +25°C for up to 5 days. Rigvir SE expiry term is 12 months.

Intake

Always use in the morning on an empty stomach with one glass of water.

Suggested use:

- For cancer prevention and immune system boosting: 1 capsule per month
- In case of suspicion of cancer or clinical pre-cancer signs are observed, including increased tumour markers: 2-4 capsules per month at equal intervals between intake
- In case of a weakened immune system: 2-4 capsules per month
- If cancer has been diagnosed, the use of Rigvir SE should be based on recommendations from healthcare professionals
- In any case, it is not recommended to exceed the amount of 6 capsules per month
- When used between toxic therapy sessions: the supplement should be taken at least 5 days before/after the intended therapy

In case of intensive Rigvir SE use, it is advised to observe the dynamics of immune parameters.

Warning

Children and pregnant or breastfeeding women should not use this supplement. Contraindications – individual intolerance to dietary supplement components. Do not use if the sachet material is punctured or missing.

Availability

Producer's webshop: www.smartnanovirus.com
Clinics, healthcare professionals.
Pharmacies, authorized distributors, and representatives.



BE ONE STEP AHEAD OF MEDICINE



INTERNATIONAL VIROTHERAPY CENTER

WORLD LEADER IN CANCER PREVENTION

International Virotherapy Center has 20 years of experience in the application of cancer virotherapy with the virus Rigvir, training healthcare professionals, accreditation of clinics, mentoring representatives, and coordination of patients around the world.

www.virotherapy.com
info@virotherapy.com

